Evogene

EVGN

Market cap $5.7M

EVGN Hedge Fund Activity: Q1 2026 in Review

15 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2026, worth a combined $409K — up 105% from $200K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVGN and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $431K. The largest seller was Citadel Advisors, exiting entirely with an estimated $97.6K sold.

• 15 institutional investors held Evogene (EVGN) as of Q1 2026, down from 18 in Q4 2025.
• Funds reported $409K of Evogene stock for Q1 2026, up 105% quarter-over-quarter.
• 2 funds opened new Evogene positions in Q1 2026 and 5 closed out, a net change of -3 holders.
• The largest Evogene buyer in Q1 2026 was Armistice Capital, an estimated $431K added.
• The largest Evogene seller in Q1 2026 was Citadel Advisors, an estimated $97.6K sold.

Based on aggregated 13F filings for Q1 2026.